-
Automated Immunoassay Analyzer
-
Bio Chemistry Analyzer
-
In Vitro Diagnostic Reagents
-
Automated Microplate Washer
-
IVD Products
-
CLIA Immunoassay Analyzer
-
POCT Immunoassay Analyzer
-
Benchtop Immunoassay Analyzer
-
Clinical Chemistry Analyzer
-
Blood Chemistry Analyzer
-
Diagnostic Lab Reagents
-
Chemiluminescence Calibrator Kit
-
Analyzer Consumables
Infectious disease diagnostic kit for closed chemiluminescent immunoassay analyzer Hepatitis B e antibody (HBeAb)
Contact me for free samples and coupons.
Whatsapp:0086 18588475571
Wechat: 0086 18588475571
Skype: sales10@aixton.com
If you have any concern, we provide 24-hour online help.
xName | HBeAb/HBeAg | Analyzer | CLIA Series |
---|---|---|---|
Luminescent Markers | AP(alkaline Phosphatase) | Calibration | 2-points |
Calibrator | Free | Quality Control | Free |
Storage | 2-8°C | Material | Magnetic Beads, Calibrators, Anti A/B, Controls |
Validity Period | 18 Months | Precision | ≤8% |
Infectious disease diagnostic kit for closed chemiluminescent immunoassay analyzer Hepatitis B e antibody (HBeAb)
HBeAg and Antibodies
Hepatitis B e antibody is a soluble viral protein. It is found early in the course of acute hepatitis B and disappears soon after ALT peaks. Persistence of HBeAg beyond 3 months after the onset of illness is unusual and may suggest progression to chronic infection.
In patients with chronic hepatitis B, the presence of positive HBeAg usually indicates a high level of viral replication and thus infectivity. HBeAg is positive in the immune tolerant phase and in the early immune clearance phase. HBeAg seroconversion is the disappearance of HBeAg and appearance of hepatitis B e antibody (anti-HBe). Most patients enter the inactive HBsAg carrier state after HBeAg seroconversion (Fig. 30-4). This state is associated with low HBV DNA, normal ALT, and little hepatic necroinflammation. However, some patients continue to have active liver disease and detectable serum HBV DNA. This can be due to either a wild-type virus or the presence of precore stop codon mutation and/or basal core promoter mutations that impair HBeAg secretion.9
HBe-AbAg: when present, especially without HBeAb, suggests increased patient infectivity.
HBeAb-total: when present, suggests less patient infectivity.
- I.
-
HBSAg positive, HBCAb negative*
-
About 5% (range 0%-17%) of patients with early-stage HBV acute infection (HBCAb rises later)
-
- II.
-
HBSAg positive, HBCAb positive, HBSAb negative
- a.
-
Most of the clinical symptom stage
- b.
-
Chronic HBV carriers without evidence of liver disease (“asymptomatic carriers”)
- c.
-
Chronic HBV hepatitis (chronic persistent type or chronic active type)
- III.
-
HBSAg negative, HBCAb positive,* HBSAb negative
- a.
-
Late clinical symptom stage or early convalescence stage (core window)
- b.
-
Chronic HBV infection with HBSAg below detection levels with current tests
- c.
-
Old previous HBV infection
- IV.
-
HBSAg negative, HBCAb positive, HBSAb positive
- a.
-
Late convalescence to complete recovery
- b.
-
Old infection
Clinical significance
(1) Chronic hepatitis B HBeAb positive accounted for 48.3%, liver cirrhosis was 68.3%, and liver cancer was 80%.
(2) The positive rate of HBeAb increased, indicating that most patients were infected with hepatitis B virus for up to 7-27 years.
(3) HBeAb positive will still be infectious to a certain extent. 20% of babies born to HBeAb-positive pregnant women are infected with hepatitis B virus.
Test Item | HBeAb |
Luminescent Principle | Enzymatic chemiluminescence |
Luminescent Markers | AP(alkaline phosphatase) |
Specification | 100/50 Tests/Kit |
/ | |
Principle | Sandwich method |
Component | Magnetic Beads |
Calibrator Low | |
Calibrator High | |
Anti-A/Anti-B | |
Control 1 | |
Control 2 | |
Accessories Required But Not Provided | Substrate |
Washing solution | |
Sample material | Serum |
Storage | 2-8℃ |